J9309 Polatuzumab Vedotin - CanMED: HCPCS

Return Home

Home

SEER Data & Software

Observational Research in Oncology Toolbox

Medication Information

CanMED: HCPCS

Generic Name:

Polatuzumab Vedotin

Brand Name:

Polivy

Strength:

1mg

HCPCS:

J9309

SEER*Rx Category:

Immunotherapy

Major Drug Class:

Drug Antibody Conjugate

Minor Drug Class:

CD79b

Oral (Y/N):

No

FDA Approval Year:

2019

FDA Discontinuation Year:

CMS Effective Date:

Jan. 1, 2020

CMS Discontinuation Date:

Status:

In Use